Resumo

SANCHEZ-SALMON, Aida  e  RUIBAL, Álvaro. Current value of positron emission tomography for prostate cancer follow-up. Arch. Esp. Urol. [online]. 2006, vol.59, n.10, pp.1021-1029. ISSN 0004-0614.

Positron emission tomography (PET) is a non-invasive nuclear medicine technology which uses radiotracers and cameras slightly different from the ones used in other nuclear medicine tests. Most current indications are for oncological diseases; in nephrology-urology its use has been reduced because of the characteristics of the most commonly used radiotracer,18F-fluor deoxiglucose (18F-FDG, a glucose analogue), which is excreted by the kidney, limiting the interpretation of the study in urologic malignancies. Currently, 18F-choline is a promising radiotracer for both staging and restaging, especially if hybrid PET/CT scan devices are used. New radiotracers will be needed in the evolution of PET to obtain information about more specific aspects of prostate carcinoma that will modify therapy and follow-up.

Palavras-chave : PET; Prostate cancer; Follow-up.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )